Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.

http://www.wikidata.org/entity/Q34309227

about

c-Met as a Target for Personalized Therapy Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.The best of both worlds - managing the cancer, saving the bone.Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1 Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

P2860

Q26775483-94EC1C20-59FF-4808-B9EF-BA8552651564 Q33623108-F8FD5C33-EAEF-4070-B74A-2297F19F3EF3 Q33920055-FECE7448-6D9A-486E-8B1B-CC9BB8756AC2 Q35889495-CEE986AB-7C61-4412-9351-5504AFC5D4BE Q38723404-C330780A-4C16-438D-A5A2-CD7DBB7D6F22 Q38751138-A15D5F6F-91A1-4789-A250-9A8004CBF042

P2860

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.

http://www.wikidata.org/entity/Q34309227

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@ast

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@en

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@nl

type

label

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@ast

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@en

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@nl

prefLabel

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@ast

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@en

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@nl

P1433

Q34309227-1569A10A-EBA2-4E6E-88D2-B99474442DD2

P1476

Q34309227-B6FF6AFE-069E-48D5-ADAB-E22393A9FF77

P2093

Q34309227-2D1C4EA9-C665-4C53-8552-CD2BF36E0602

Q34309227-3DE360EA-06B1-466F-84B5-A8BCD9DE5842

Q34309227-8927BCB1-C300-4E42-91DB-5A81CD660852

Q34309227-A8FDDCD1-8CBC-4344-B8D7-DC9F1A92DE0D

Q34309227-B27D93AF-8C16-4EF3-B8CE-99BB2C2E8DBA

Q34309227-E1FD1F80-C86C-440C-A6C0-5BF8F5D6B7EA

Q34309227-E228B560-77EF-40E0-8948-BB2C8A4BACAB

Q34309227-E38419D0-25F6-49A7-9C2E-B2F0C80FB306

Q34309227-FBAF5543-BA2E-4519-88EF-7AA9A6C68B2B

P2860

Q34309227-0271A522-D862-4E63-B7D7-FFC3C4D593A0

Q34309227-104F5D38-EA27-49F1-B047-7FBD4FDD6401

Q34309227-21737DE2-31A5-42BE-8215-0FE524DA57D3

Q34309227-25525856-B667-4050-B4A7-2A1FC98B7038

Q34309227-25CBEF4A-6DDC-4AF2-80C4-66A48AC12E65

Q34309227-26EA09E1-B028-4149-A85A-4062D33B2182

Q34309227-26F3480C-A1C8-4AB9-9445-61E09B0EC869

Q34309227-2A760EF8-9178-47A0-A9D5-D4EEBD049A12

Q34309227-32A66563-C37E-4300-BDE0-0E616B1647AD

Q34309227-44017320-0816-434F-A084-FBB1279447A4

P2888

Q34309227-EDACB787-875F-45F4-A11B-19B81F1B0A0F

P304

Q34309227-307F5A39-8387-4F37-A50E-FFCA0BC4C109

P31

Q34309227-C2A6E0E9-4489-4706-9E69-D5619EFCD1EB

P356

Q34309227-E9C76679-62A3-484D-AADF-3EC9AD50E153

P407

Q34309227-918FA2DD-355A-4BA8-BDB4-019CAF6CC7C1

P478

Q34309227-37624A5F-71C8-41EF-96AB-C63FD2D36042

P577

Q34309227-489AE157-80FE-4A51-9A73-680A20FC8C5A

P5875

Q34309227-7C45B2FC-6984-4EA4-8EEB-CDD795E390F7

P6179

Q34309227-9CA9FF5C-7548-4F07-A2C7-3B72EBC2D639

P698

Q34309227-6A9E7F9A-909E-4305-A669-E06D7D6B4DF9

P921

Q34309227-251F00C4-98B2-4878-85CD-AE2725CAFCB2

P932

Q34309227-A5F4CA46-B0B3-4B15-9C10-C883B63FEA4D

P356

1471-2407-14-742

P1433

P1476

Axitinib and crizotinib combin ...... ion resistant prostate cancer.

@en

P2093

Anand Giddabasappa

http://www.w3.org/2001/XMLSchema#string

Gang Li

http://www.w3.org/2001/XMLSchema#string

Guangzhou Han

http://www.w3.org/2001/XMLSchema#string

James Christensen

http://www.w3.org/2001/XMLSchema#string

Jeetendra Eswaraka

http://www.w3.org/2001/XMLSchema#string

Koleen Eisele

http://www.w3.org/2001/XMLSchema#string

Kush Lalwani

http://www.w3.org/2001/XMLSchema#string

Timothy Affolter

http://www.w3.org/2001/XMLSchema#string

Zheng Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Cancer statistics, 2010

Cancer statistics, 2013

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

Met, metastasis, motility and more

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

High expression of the Met receptor in prostate cancer metastasis to bone.

Treatment and prevention of bone complications from prostate cancer.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

P2888

1471-2407-14-742

P304

742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-742

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266582495

http://www.w3.org/2001/XMLSchema#string

P6179

1020957346

http://www.w3.org/2001/XMLSchema#string

P698

25277255

http://www.w3.org/2001/XMLSchema#string

P921

P932

4190397

http://www.w3.org/2001/XMLSchema#string